Zosano Pharma Corporation announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed brand name Qtrypta for M207, the Companys investigational drug for treatment of migraine. A request for proprietary name review and final approval for Qtrypta will be included when Zosano submits a New Drug Application (NDA) for M207. The name Qtrypta (pronounced "kew-trip-tah") was developed in compliance with the FDA's Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names. The proprietary name development program included research with physicians and pharmacists, and FDA™ conditional approval validated Qtrypta is a proprietary name that is consistent with the FDA's goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use. Final approval of the Qtrypta brand name is conditional on FDA approval of the product candidate, M207.